Key result
Adenosine and calcium channel blockers demonstrated equal efficacy in converting paroxysmal supraventricular tachycardia to normal sinus rhythm, though adenosine was associated with a quicker onset, higher cost, and higher recurrence rate.
Why the study?
Adenosine is currently the drug of choice for paroxysmal supraventricular tachycardia when vagal maneuvers fail, but calcium channel blockers are also used, prompting a comparison of their efficacy.
Do calcium channel blockers improve reversion to normal sinus rhythm and safety compared to adenosine in patients with paroxysmal supraventricular tachycardia?
Population
32 studies in humans with paroxysmal supraventricular tachycardia
Comparison
Calcium channel blockers vs adenosine
Design
Systematic review
Authors
Loading...
Supports adenosine as first-line for acute PSVT due to onset speed; confirms equivalent efficacy versus calcium channel blockers.
Systematic Review (n=3,111)
Do calcium channel blockers improve reversion to normal sinus rhythm and safety compared to adenosine in patients with paroxysmal supraventricular tachycardia?
Both adenosine and calcium channel blockers are equally effective in terminating PSVT, but adenosine has a quicker onset, higher cost, and higher recurrence rate, supporting its use as first-line therapy with potential follow-up oral CCBs.
Ahmad et al. (2021) conducted a systematic review in Paroxysmal Supraventricular Tachycardia (PSVT) (n=3,111). Adenosine vs. Calcium channel blockers (Verapamil or Diltiazem) was evaluated on Reversion to normal sinus rhythm. Adenosine and calcium channel blockers demonstrated equal efficacy in converting paroxysmal supraventricular tachycardia to normal sinus rhythm, though adenosine was associated with a quicker onset, higher cost, and higher recurrence rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: